Table. Characteristics of Included Cohort Studies and Participants Treated With TCIs.
| Source | Participant source (location) | Method of identifying cancer | Condition | Treatment | Exposed cohort | Follow-up time, y | |||
|---|---|---|---|---|---|---|---|---|---|
| No. | Age, mean (SD), y | Female, % | |||||||
| Asgari et al,24 2020 | KPNC health plan members (aged ≥40 y) with AD or dermatitis from 01/01/2002 through 12/31/2013 (US) | KPNC electronic pathology database; codes reviewed by dermatologist blinded to exposure | AD and dermatitis | TCI | 7033 | NA | 70.6 | Mean, 7.7a | |
| Cai et al,20 2016 | All patients with atopic and endogenous eczema seen at the National Skin Centre from 01/2004 to 12/2012 (Singapore) | Singapore Cancer Registry | Atopic and endogenous eczema | Tacrolimus | 3020 | 24.4 (18.3) | 48.8 | Mean, 3.8 | |
| Pimecrolimus | 1279 | 18.9 (17.3) | 52.6 | Mean, 4.9 | |||||
| Castellsague et al,21 2018 | PHARMO Database Network in the Netherlands, the Danish and Swedish national health registers, and the CPRD in the UK, from 2002 to 2011 (Europe) | (1) Cancer registries in Denmark, Sweden, and CPRD; (2) Dutch National Pathology Registry; (3) Primary care records in CPRD | AD | Tacrolimus | 86 075 | NA | 58.7 | Mean range, 2.2-4.2 | |
| Pimecrolimus | 60 257 | NA | 58.6 | Mean range, 2.8-6.5 | |||||
| Deleuran et al,9 2016 | Danish Cancer Registry exposed to treatment from 2002 to 2009 (Denmark) | Danish Cancer Registry | AD | TCI | 34 921 | NA | NA | NA | |
| Hui et al,8 2009 | Kaiser Permanente (California) health care consortium member with a diagnosis of AD or eczema from 01/2001 to 12/2004 (US) | KPNC and Kaiser Permanente Southern California Cancer Registry | AD and eczema | Tacrolimus | 15 966 | 34.1 (23.5) | 60.4 | Median, 2.4 | |
| Pimecrolimus | 26 784 | 29.7 (23.8) | 62.8 | Median, 1.9 | |||||
| Margolis et al,22 2015 | PEER study from start in 2004 to 05/2014 (US) | Study participants queried every 6 mo | AD | Pimecrolimus | 7457 | 7.2 (4.0) | 53.2 | 3.6a | |
| Paller et al,25 2020 | Children enrolled in the APPLES study beginning in 05/2005 and terminating on 01/31/2019 (multinational) | Families responded twice yearly to questionnaire or telephone interview regarding child’s AD therapy | AD | Tacrolimus | 7954 | 7.1 (NA) | 52.4 | Approximately 10 | |
| Schneeweiss et al,23 2009 | Health insurance claims database affiliated with Ingenix Research Data Mart from 01/01/2002 to 06/30/2006 (US) | Claims data and medical records adjudicated by oncologists | Dermatitis (seborrheic dermatitis, AD, contact dermatitis, sunburn) | Tacrolimus | 38 757 | NA | 57 | Mean, 1.5 | |
| Pimecrolimus | 118 863 | NA | 58 | Mean, 1.5 | |||||
Abbreviations: AD, atopic dermatitis; APPLES, A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis; CPRD, Clinical Practice Research Datalink; KPNC, Kaiser Permanente Northern California; NA, not available; PEER, Pediatric Eczema Elective Registry; TCI, topical calcineurin inhibitor.
a
Calculated from person-years.